Joanne Wuensch

“I do have a memory of ebbs and flows in the orthopedics market, and they hit the name market. But generally, could you remind what brought us out the last time, and what can be learned from that to think about bringing this out this time?”

“Could you maybe characterize a bit more what you're seeing in the market and contact lenses in the U.S. and outside the U.S., and then maybe talk a little bit, you know, about competition?”

“Good morning, and thank you so much for taking the question, and congrats on the nutrition Briefly, can you comment on potential reimbursement from CMS for non-intensive type 2 for CGM use?”

“To wrap it up, I think I'll ask about Charlotte, North Carolina, and why are we going there and what can we expect from the analyst meeting? And my second question sort of probably ties to that one.”

“Based on your commentary for summer of 27 FDA approval. It sounds like your milestone payment will be more of a first quarter fiscal year 28 than a second quarter fiscal year 28 event.”